Has the TGA received submission from Starpharma for VIRALEZE™ Antiviral Nasal Spray

Has the TGA received submission from Starpharma for VIRALEZE™ Antiviral Nasal Spray

Below are the relevant announcement excerpts with time stamps

You be the judge


July 5th
Starpharma is currently negotiating distribution and marketing arrangements for VIRALEZE™ in a number of countries which include India, various European countries and other international regions.

June 21st
VIRALEZE™ is not yet approved in Australia

June 11th
Starpharma is also progressing regulatory activities for a number of markets, including Australia. The Company will make further announcements upon registration and launch of the product in other countries/regions.

June 1st
Starpharma is pursuing avenues to provide rapid access to VIRALEZE™ in a number of countries where outbreaks have occurred. Starpharma is exploring expedited registration where applicable. The Company is also progressing other regulatory activities for a number of markets, including Australia. Starpharma will make further announcements upon registration and launch of the product in other countries/regions.

May 6th
VIRALEZE™ is registered in the EU. Starpharma is pursuing avenues to provide rapid access to VIRALEZE™ in India, including opportunities for expedited registration and distribution in the region. The Company is also progressing regulatory activities for a number of markets, including Australia, with the intention to roll it out across multiple markets.

April 28th
Starpharma is pursuing avenues to provide rapid access to VIRALEZE™ in India, including opportunities for expedited registration and distribution in the region. The Company is also progressing regulatory activities for a number of markets, including Australia. Starpharma will make further announcements upon registration and launch of the product in other countries/regions.

April 27th
Starpharma is leveraging the European registration of VIRALEZE™ to expedite further marketing approvals for the product as soon as practicable in other countries, including Australia.

March 30th
Starpharma also plans to roll the product out across Europe, and to seek registration for the product in other regions, including Australia.

February 23rd
The European registration of VIRALEZE™ and the regulatory dossier will be used as the basis for obtaining further marketing approvals for the product as soon as practicable in other countries, including in Australia.

December 10th 2020
Europe will be the first geographic region for the VIRALEZE™ launch. Starpharma plans to leverage the European registration to roll-out VIRALEZE™ into other markets including Australia as quickly as possible